Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
about
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceTyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophagesTargeting Btk/Etk of prostate cancer cells by a novel dual inhibitorNew strategies in the treatment of multiple myeloma.Novel therapeutic targets in myeloma bone disease.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLInhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Bone disease in multiple myeloma: pathophysiology and management.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cellsRole of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in miceSotatercept in patients with osteolytic lesions of multiple myeloma.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaThe novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesIncidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesNovel Bruton's tyrosine kinase inhibitors currently in development.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseBone marrow microenvironment in cancer patients: immunological aspects and clinical implications.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.Overcoming bortezomib resistance in multiple myeloma.
P2860
Q26765477-ACBE2515-F3F2-4549-B238-29B2B73C0AEEQ26785497-54923F04-F962-4C70-A534-668B23C45B6AQ26822700-37B51730-8E92-461E-8BDE-C88FBB9CCF23Q27025812-E288D1FB-D237-4E0A-A482-7608B721ED80Q27687567-439B07D4-3E07-450B-84DB-67CB25630352Q28395203-08B015AB-E6B2-44EF-9901-1BA864075E14Q30615575-E1AB0DE6-889C-4631-B9E9-02BF1B0C2BEFQ30661625-9AF17F4B-44FB-4E0A-B26D-461065224B00Q33958520-E45344E0-0D27-4833-8122-DF9BD9005939Q34025065-313A6CF9-820B-426E-81C2-66B79D95E198Q34039406-EDE782EB-254C-4CF5-8156-E9AB9CE7ABD1Q34042250-43817A7E-7631-4649-A162-E25BBCE961ABQ34042407-4E115691-E205-42D6-B8F1-5F99CC7DE95BQ34045789-1A600302-F67F-46BA-BBB5-B0A68A486655Q34067085-C2CFB38A-1881-4A41-B67D-5C1023E3BD86Q34354339-1F4C2B5D-E092-4684-A562-DEE6A1B4508CQ34448984-3D3D1D30-17C9-4CA5-AC35-CCCBB5F97331Q34722000-405D1C90-35C4-40A0-8C44-206AFAA3B7B4Q34773850-0DD2897A-80C1-49CE-B820-3DBDFA56D833Q34861202-4D0CC90C-2C3E-4C81-AA0C-1592980B8599Q35035011-B0FFD2FA-470E-4064-966A-C01F23039CA1Q35067806-C754E541-B544-4ADA-ADF6-4A4518CC3DB5Q35260732-A2B6D6B8-C28D-4938-B6CF-F4E5A446CA95Q35889653-87AC8D07-3873-4728-820E-04A1264F4D74Q35979385-77F61728-1E59-4201-83D4-26C7F896D64EQ36020943-7C2FB6A8-20D8-490E-898B-EE47A6C88C1BQ36183770-01F5FEA7-753C-47B8-84A9-51B3EE80F8E3Q36334833-A0F1031D-D16F-469D-9C9A-1259BA415BE6Q36337598-CCDBC1B6-77CB-4E0E-B649-FC462AB6BDEAQ36602853-FAE05BF9-FE63-4CD3-9F78-31D1A9FC3B55Q36673755-E731E0CE-EB94-47C8-B749-DF7ACBC3132FQ36810546-59896B55-97A6-45FC-82DD-8998421ABD2FQ37035836-98055100-4E45-443C-9AC0-8792F431CC4DQ37445828-E778EB15-3B73-4E6F-8B13-BC52FEA99EEBQ37552008-EF8B27CE-BE43-4998-8ACA-81B8C0D2637BQ37678085-CFD9D12A-BE6A-4BDD-85F7-8EC76E12428AQ38053396-E63B0AEC-66CF-45FB-A1BE-118A734F4493Q38083077-DF550186-DE33-4D8E-8564-BC984D217D54Q38171390-8C6634BC-B1C1-4512-B3D5-D89496733BA9Q38238610-D31837F0-A8B3-40D3-87E9-2EC053A3A142
P2860
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@ast
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@en
type
label
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@ast
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@en
prefLabel
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@ast
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@en
P2093
P2860
P50
P1433
P1476
Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma
@en
P2093
Antonia Cagnetta
Betty Y Chang
Chirag Acharya
Daniel R Carrasco
Guang Yang
Jian-Jun Zhao
Jianhong Lin
Joseph J Buggy
Laurence Elias
Mariateresa Fulciniti
P2860
P304
P356
10.1182/BLOOD-2011-12-396853
P407
P577
2012-06-11T00:00:00Z